AngioLab Inc
251280
Company Profile
Business description
AngioLab Inc is a biotechnology company. It is developing pharmaceuticals and health functional foods based on the inhibition of angiogenesis. The group is developing natural products and antibody-based pharmaceuticals.
Contact
65, 122, 159, Techno 3-ro
Yuseong-gu
Gwanpyeong-dong, Hanshin S Mecca
Daejeon
KORT: +82 428675785
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
16
Stocks News & Analysis
stocks
More gas left in the tank for ASX highflyer
Shares jumped after results and are screening as overvalued.
stocks
Ahead of Earnings, is Apple stock a buy, a sell, or fairly valued?
Following strong holiday sales and a recent AI deal, here’s what we’re watching for in Apple’s earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,189.90 | 15.70 | 0.17% |
| CAC 40 | 8,113.17 | 29.88 | -0.37% |
| DAX 40 | 24,831.61 | 69.10 | -0.28% |
| Dow JONES (US) | 49,098.71 | 285.30 | -0.58% |
| FTSE 100 | 10,148.78 | 5.34 | 0.05% |
| HKSE | 26,765.52 | 16.01 | 0.06% |
| NASDAQ | 23,501.24 | 65.22 | 0.28% |
| Nikkei 225 | 52,885.25 | 961.62 | -1.79% |
| NZX 50 Index | 13,460.74 | 12.50 | 0.09% |
| S&P 500 | 6,915.61 | 2.26 | 0.03% |
| S&P/ASX 200 | 8,860.10 | 15.00 | 0.17% |
| SSE Composite Index | 4,132.60 | 3.56 | -0.09% |